Loading quotes...

Forecast

The analysts' average price target is €5.36 (+387.27%). The median is €5.36 (+387.27%).

Buy	11
Hold	1
Sell	0

News Go to news feed

Equillium presents clinical strategy for AHR program EQ504 and starts phase I in Australia

At the Cantor Fitzgerald Healthcare Conference Equillium presented the development of EQ504, a differentiated AHR modulator with anti-inflammatory and wound-healing properties. The company is well capitalized after earlier financing rounds and an investment from RA Capital; administration of the first phase I dose will trigger an additional tranche of USD 20 million. The SAD/MAD phase I study in healthy volunteers has been submitted to Australian authorities and could deliver top-line data six months after study start. Equillium is also working on an inhaled lung formulation and a colon-targeted capsule, prioritizing ulcerative colitis with later expansion into lung diseases. » More on de.investing.com
Equillium realigns leadership and focuses pipeline on drug candidate EQ504

Equillium reorganized management and the board, promoted Dr. Stephen Connelly to president while he remains active as CSO, and shortened the board; Daniel M. Bradbury remains chairman and Bruce Steel remains CEO. The company ended its collaboration on itolizumab and is concentrating on EQ504, a multimodal, non‑immunosuppressive aryl‑hydrocarbon receptor modulator with potential oral and inhaled formulations for inflammatory diseases. To strengthen the balance sheet, Equillium announced a prospectus supplement for share sales of up to $75 million, a private placement of up to $50 million (including a $30 million upfront payment), and the integration of cryptocurrencies into its treasury strategy. » More on de.investing.com
Equillium files prospectus supplement for stock offering of up to $75 million

Equillium has filed a prospectus supplement with the U.S. SEC for an offering and sale of common stock totaling up to $75 million under an open market sale agreement with LifeSci Capital. Under that agreement, 1,719,485 shares have already been sold, producing gross proceeds of $0.96 million. The company also reported a private placement of up to $50 million, with a $30 million advance for about 52.6 million shares at $0.57 per share and a potential additional $20 million contingent on milestone achievements. Equillium additionally announced plans to integrate cryptocurrencies into its treasury strategy; the stock is currently trading at $1.46 and the company has a market capitalization of $88 million. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2008, Equillium has already paid €0.49 in dividends. The last payout was in September 2008.

Financials

In the last quarter, Equillium had revenue of €0 and net profit of -€4.11M

(EUR)	June 2026	YoY
Revenue	0	-
Gross profit	0	100.00%
Net profit	-4.11M	15.55%
EBITDA	-4.45M	8.03%

Fundamentals

Metric	Value
Market capitalization	€69.62M
Number of shares	63.41M
52-week high/low	€3.16 - €0.68
Dividends	No
Beta	1.92
P/E ratio	-4.80
PEG ratio	-0.08
P/B ratio	2.46
P/S ratio	0.00

Company profile

Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase Ib clinical trial for the treatment of asthma disease; and Phase Ib clinical trial for the treatment of and lupus nephritis. It also develops EQ101 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ102 to treat various gastrointestinal diseases. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.